Corporate profile
3M Drug Delivery Systems is a global leader providing pharmaceutical and biotechnology companies with innovative drug delivery solutions ranging from MDIs to DPIs for inhalation and conventional or novel transdermal technology. 3M provides partners flexibility in working arrangements for development through commercialization and expertise to help you get to market sooner. We combine the agility of a leading company with the resources of a major, multinational corporation supported by 3M's annual R&D budget of more than $1 billion.
3M's corporate headquarters and research center in St. Paul, Minnesota.
Successfully teaming our delivery technology with molecules from many major pharmaceutical firms has helped make us a world leader in inhalation and transdermal drug delivery. 3M's proven track record includes development of the first metered-dose inhaler (MDI), development of the first CFC-free MDI, and development of the first 7-day transdermal system. Recently, we have added a novel dry-powder inhaler to the technology portfolio we can offer clients. Products manufactured by 3M Drug Delivery Systems currently are sold in more than 60 countries on 6 continents.
3M in-house resources are available to support each step of the development process from early stages through post-approval. Corporate resources include technology centers and divisions producing component materials. In-house resources include pharmacokinetics, drug metabolism, clinical affairs, toxicology, analytical, regulatory affairs, quality assurance, operations, and marketed product support.
Whether accessing our systems development capabilities or using our transdermal or inhalation components for your own development program, you will benefit from our global development, regulatory, and manufacturing expertise.
3M Drug Delivery Systems
3M Center
Bldg. 275-3E-10
St. Paul, MN 55144-1000
Telephone: 800.643.8086
Fax: 651.633.2072
Web site: www.3M.com/DDS
Number of employees:
USA: 35,024
Outside USA: 33,750
Date founded: 1902
AAPS PharmSci 360 2024: Predictive Models for Poorly Soluble Drugs
October 10th 2024Pharmaceutical Technology sat down with Niloufar Salehi, advisor at Eli Lilly & Company, to talk about the session she is moderating at AAPS PharmSci 360 2024, Symposium: An Accelerated Development of Poorly Soluble Drugs Using Predictive Tool.